Consent for genetics studies among clinical trial participants: findings from Action for Health in Diabetes (Look AHEAD)
Authors:
- M A EspelandMEM A Espeland
- K DotsonKDK Dotson
- S A JaramilloSJS A Jaramillo
- S E KahnSKS E Kahn
- B HarrisonBHB Harrison
- M MontezMMM Montez
- J P ForeytJFJ P Foreyt
- W C KnowlerWKW C Knowler
- Look AHEAD Research GroupLGLook AHEAD Research Group
Open Access
- 1 October 2006
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 3 (5) , 443-456
Abstract
Background Increasingly, genetic specimens are collected to expand the value of clinical trials through study of genetic effects on disease incidence, progression or response to interventions. Purpose and methods We describe the experience obtaining IRB-approved DNA consent forms across the 19 institutions in the Action for Health in Diabetes (Look AHEAD), a clinical trial examining the effect of a lifestyle intervention for weight loss on the risk of serious cardiovascular events among individuals with type 2 diabetes. We document the rates participants provided consent for DNA research, identify participant characteristics associated with consent, and discuss implications for genetics research. Results IRB approval to participate was obtained from 17 of 19 institutions. The overall rate of consent was 89.6% among the 15 institutions that had completed consenting at the time of our analysis, which was higher than reported for other types of cohort studies. Consent rates were associated with factors expected to be associated with weight loss and cardiovascular disease and to affect the distribution of candidate genes. Non-consent occurred more frequently among participants grouped as African-American, Hispanic, female, more highly educated or not dyslipidemic. Limitations The generalizabilty of results is limited by the inclusion/exclusion criteria of the trial. Conclusions Barriers to obtaining consent to participate in genetic studies may differ from other recruitment settings. Because of the potentially complex associations between personal characteristics related to adherence, outcomes and gene distributions, differential rates of consent may introduce biases in estimates of genetic relationships. Background Increasingly, genetic specimens are collected to expand the value of clinical trials through study of genetic effects on disease incidence, progression or response to interventions. Purpose and methods We describe the experience obtaining IRB-approved DNA consent forms across the 19 institutions in the Action for Health in Diabetes (Look AHEAD), a clinical trial examining the effect of a lifestyle intervention for weight loss on the risk of serious cardiovascular events among individuals with type 2 diabetes. We document the rates participants provided consent for DNA research, identify participant characteristics associated with consent, and discuss implications for genetics research. Results IRB approval to participate was obtained from 17 of 19 institutions. The overall rate of consent was 89.6% among the 15 institutions that had completed consenting at the time of our analysis, which was higher than reported for other types of cohort studies. Consent rates were associated with factors expected to be associated with weight loss and cardiovascular disease and to affect the distribution of candidate genes. Non-consent occurred more frequently among participants grouped as African-American, Hispanic, female, more highly educated or not dyslipidemic. Limitations The generalizabilty of results is limited by the inclusion/exclusion criteria of the trial. Conclusions Barriers to obtaining consent to participate in genetic studies may differ from other recruitment settings. Because of the potentially complex associations between personal characteristics related to adherence, outcomes and gene distributions, differential rates of consent may introduce biases in estimates of genetic relationships.Keywords
This publication has 30 references indexed in Scilit:
- Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetesControlled Clinical Trials, 2003
- A community-driven model of research participation: The Jackson Heart Study participant recruitment and retention study2003
- Principles, organization, and operation of a DNA bank for clinical trials:Controlled Clinical Trials, 2002
- Informed Consent and the Capacity for VoluntarismAmerican Journal of Psychiatry, 2002
- Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trialsInternational Journal of Obesity, 2002
- Recruitment of American Indians in Epidemiologic Research: The Strong Heart StudyAmerican Indian and Alaska Native Mental Health Research, 2000
- Ethical and Legal Issues in Genetic EpidemiologyEpidemiologic Reviews, 1997
- Healthy volunteer effect in a cohort study: Temporal resolution in the adventist health studyJournal of Clinical Epidemiology, 1996
- Clinical trial enrollers vs. nonenrollers: The Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) projectControlled Clinical Trials, 1996
- Non-participation and mortality in a prospective study of cardiovascular disease.Journal of Epidemiology and Community Health, 1987